Last reviewed · How we verify
NCT01351103
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Phase 1 trial testing LGK974 in Pancreatic Cancer in 185 participants. Completed in 17 June 2024.
1 June 2021
Quick facts
| Lead sponsor | Novartis Pharmaceuticals |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 185 |
| Start date | 1 December 2011 |
| Primary completion | 1 June 2021 |
| Estimated completion | 17 June 2024 |
| Sites | 20 locations across France, Italy, Netherlands, Germany, Canada, United States, Spain |
Drugs / interventions tested
Conditions studied
- Pancreatic Cancer — all drugs for Pancreatic Cancer →
- BRAF Mutant Colorectal Cancer — all drugs for BRAF Mutant Colorectal Cancer →
- Melanoma — all drugs for Melanoma →
- Triple Negative Breast Cancer — all drugs for Triple Negative Breast Cancer →
Sponsor
Novartis Pharmaceuticals — full company profile →
Who can join
18 and older, any sex, with Pancreatic Cancer or BRAF Mutant Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary purpose of this study was to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given to adult patients with selected solid malignancies that had progressed despite standard therapy or for which no effective standard therapy existed.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting cancer stem cell pathways for cancer therapy.
Yang L, Shi P, Zhao G, Xu J, et al · · 2020 · cited 1354× · PMID 32296030 · DOI 10.1038/s41392-020-0110-5 -
Comprehensive review of targeted therapy for colorectal cancer.
Xie YH, Chen YX, Fang JY. · · 2020 · cited 1162× · PMID 32296018 · DOI 10.1038/s41392-020-0116-z -
Targeting the Wnt/β-catenin signaling pathway in cancer.
Zhang Y, Wang X. · · 2020 · cited 1065× · PMID 33276800 · DOI 10.1186/s13045-020-00990-3 -
Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update.
Takebe N, Miele L, Harris PJ, Jeong W, et al · · 2015 · cited 1034× · PMID 25850553 · DOI 10.1038/nrclinonc.2015.61 -
Emerging targets in neuroinflammation-driven chronic pain.
Ji RR, Xu ZZ, Gao YJ. · · 2014 · cited 836× · PMID 24948120 · DOI 10.1038/nrd4334 -
Tackling the cancer stem cells - what challenges do they pose?
Pattabiraman DR, Weinberg RA. · · 2014 · cited 798× · PMID 24981363 · DOI 10.1038/nrd4253 -
Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors.
Krishnamurthy N, Kurzrock R. · · 2018 · cited 784× · PMID 29169144 · DOI 10.1016/j.ctrv.2017.11.002 -
Recent advances in therapeutic strategies for triple-negative breast cancer.
Li Y, Zhang H, Merkher Y, Chen L, et al · · 2022 · cited 643× · PMID 36038913 · DOI 10.1186/s13045-022-01341-0
Verify or expand the search:
- PubMed search for NCT01351103
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreatic Cancer
Currently open trials in the same condition.
- NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
- NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
- NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting
Other Novartis Pharmaceuticals trials
Trials by the same sponsor.
- NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
- NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
- NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
- NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
- NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01351103 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
- Last refreshed: 13 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01351103.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing